252 related articles for article (PubMed ID: 31456190)
21. TIS21
Sundaramoorthy S; Devanand P; Ryu MS; Song KY; Noh DY; Lim IK
J Cancer Res Clin Oncol; 2018 Aug; 144(8):1445-1462. PubMed ID: 29808317
[TBL] [Abstract][Full Text] [Related]
22. Targeting of mTORC2 may have advantages over selective targeting of mTORC1 in the treatment of malignant pheochromocytoma.
Zhang X; Wang X; Xu T; Zhong S; Shen Z
Tumour Biol; 2015 Jul; 36(7):5273-81. PubMed ID: 25666752
[TBL] [Abstract][Full Text] [Related]
23. UCH-L1 bypasses mTOR to promote protein biosynthesis and is required for MYC-driven lymphomagenesis in mice.
Hussain S; Bedekovics T; Liu Q; Hu W; Jeon H; Johnson SH; Vasmatzis G; May DG; Roux KJ; Galardy PJ
Blood; 2018 Dec; 132(24):2564-2574. PubMed ID: 30257881
[TBL] [Abstract][Full Text] [Related]
24. Structural mechanisms of the mTOR pathway.
Linde-Garelli KY; Rogala KB
Curr Opin Struct Biol; 2023 Oct; 82():102663. PubMed ID: 37572585
[TBL] [Abstract][Full Text] [Related]
25. A bi-steric mTORC1-selective inhibitor overcomes drug resistance in breast cancer.
Meng D; Zhao X; Yang YC; Navickas A; Helland C; Goodarzi H; Singh M; Bandyopadhyay S
Oncogene; 2023 Jul; 42(28):2207-2217. PubMed ID: 37264081
[TBL] [Abstract][Full Text] [Related]
26. Dysregulation of mTOR Signaling after Brain Ischemia.
Villa-González M; Martín-López G; Pérez-Álvarez MJ
Int J Mol Sci; 2022 Mar; 23(5):. PubMed ID: 35269956
[TBL] [Abstract][Full Text] [Related]
27. mTOR modulates resistance to gemcitabine in lung cancer in an MTORC2 dependent mechanism.
Chawsheen MA; Dash PR
Cell Signal; 2021 May; 81():109934. PubMed ID: 33545231
[TBL] [Abstract][Full Text] [Related]
28. Targeting mTOR in Glioblastoma: Rationale and Preclinical/Clinical Evidence.
Mecca C; Giambanco I; Donato R; Arcuri C
Dis Markers; 2018; 2018():9230479. PubMed ID: 30662577
[TBL] [Abstract][Full Text] [Related]
29. Advances in understanding the mechanisms of evasive and innate resistance to mTOR inhibition in cancer cells.
Chiarini F; Evangelisti C; Lattanzi G; McCubrey JA; Martelli AM
Biochim Biophys Acta Mol Cell Res; 2019 Aug; 1866(8):1322-1337. PubMed ID: 30928610
[TBL] [Abstract][Full Text] [Related]
30. Growth or death? Control of cell destiny by mTOR and autophagy pathways.
Khalil MI; Ali MM; Holail J; Houssein M
Prog Biophys Mol Biol; 2023 Dec; 185():39-55. PubMed ID: 37944568
[TBL] [Abstract][Full Text] [Related]
31. mTOR controls embryonic and adult myogenesis via mTORC1.
Rion N; Castets P; Lin S; Enderle L; Reinhard JR; Eickhorst C; Rüegg MA
Development; 2019 Apr; 146(7):. PubMed ID: 30872276
[TBL] [Abstract][Full Text] [Related]
32. The mTOR pathway in reproduction: from gonadal function to developmental coordination.
Correia B; Sousa MI; Ramalho-Santos J
Reproduction; 2020 Apr; 159(4):R173-R188. PubMed ID: 31786539
[TBL] [Abstract][Full Text] [Related]
33. Small molecules bind human mTOR protein and inhibit mTORC1 specifically.
Allen SA; Tomilov A; Cortopassi GA
Biochem Pharmacol; 2018 Sep; 155():298-304. PubMed ID: 30028993
[TBL] [Abstract][Full Text] [Related]
34. Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer.
Li H; Lin J; Wang X; Yao G; Wang L; Zheng H; Yang C; Jia C; Liu A; Bai X
Breast Cancer Res Treat; 2012 Aug; 134(3):1057-66. PubMed ID: 22476852
[TBL] [Abstract][Full Text] [Related]
35. The mTOR Kinase Inhibitor CZ415 Inhibits Human Papillary Thyroid Carcinoma Cell Growth.
Li X; Li Z; Song Y; Liu W; Liu Z
Cell Physiol Biochem; 2018; 46(2):579-590. PubMed ID: 29617677
[TBL] [Abstract][Full Text] [Related]
36. Mechanistic target of rapamycin: integrating growth factor and nutrient signaling in the collecting duct.
Brown AL; Fluitt MB; Ecelbarger CM
Am J Physiol Renal Physiol; 2018 Sep; 315(3):F413-F416. PubMed ID: 29846113
[TBL] [Abstract][Full Text] [Related]
37. Using
Frappaolo A; Giansanti MG
Cells; 2023 Nov; 12(22):. PubMed ID: 37998357
[TBL] [Abstract][Full Text] [Related]
38. mTOR signaling at the crossroads of environmental signals and T-cell fate decisions.
Huang H; Long L; Zhou P; Chapman NM; Chi H
Immunol Rev; 2020 May; 295(1):15-38. PubMed ID: 32212344
[TBL] [Abstract][Full Text] [Related]
39. Role of the Mammalian Target of Rapamycin Pathway in Liver Cancer: From Molecular Genetics to Targeted Therapies.
Lu X; Paliogiannis P; Calvisi DF; Chen X
Hepatology; 2021 Jan; 73 Suppl 1(Suppl 1):49-61. PubMed ID: 32394479
[TBL] [Abstract][Full Text] [Related]
40. Regulation and metabolic functions of mTORC1 and mTORC2.
Szwed A; Kim E; Jacinto E
Physiol Rev; 2021 Jul; 101(3):1371-1426. PubMed ID: 33599151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
